MyoKardia (MYOK) Tops Q4 EPS by 20c

MyoKardia (NASDAQ: MYOK) reported Q4 EPS of ($0.21), $0.20 better than the analyst estimate of ($0.41). Collaboration & License revenue for the quarter came in at $5.6 million versus the consensus estimate of $6.08 million.

For earnings history and earnings-related data on MyoKardia (MYOK) click here.

You May Also Be Interested In

• Nomura/Instinet Upgrades Genting Singapore (GENS:SP) (GIGNY) to Neutral
• RCM Technologies (RCMT) Tops Q2 EPS by 17c
• Calidi Biotherapeutics (CLDI) Reports Q2 Loss of $2.94